Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the num...
Gespeichert in:
| Veröffentlicht in: | Pharmacology & therapeutics (Oxford) 2003-02, Vol.97 (2), p.153-179 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 179 |
|---|---|
| container_issue | 2 |
| container_start_page | 153 |
| container_title | Pharmacology & therapeutics (Oxford) |
| container_volume | 97 |
| creator | Konradi, Christine Heckers, Stephan |
| description | The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the number of their connections are determined by the activity of the glutamate system and its receptors. Malfunctions of the glutamate system affect neuroplasticity and can cause neuronal toxicity. In schizophrenia, many glutamate-regulated processes seem to be perturbed. Abnormal neuronal development, abnormal synaptic plasticity, and neurodegeneration have been proposed to be causal or contributing factors in schizophrenia. Interestingly, it seems that the glutamate system is dysregulated and that
N-methyl-
d-aspartate receptors operate at reduced activity. Here we discuss how the molecular aspects of glutamate malfunction can explain some of the neuropathology observed in schizophrenia, and how the available treatment intervenes through the glutamate system. |
| doi_str_mv | 10.1016/S0163-7258(02)00328-5 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4203361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163725802003285</els_id><sourcerecordid>12559388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-60245ae36749ba2efbcae80efb3a622ef88c123602d4a1130e4c268353cbebc43</originalsourceid><addsrcrecordid>eNqFUEtLAzEQDqJorf4EJUc9rOax2aYeFCm-QPGggidDNjvbRnY3S7It1F9v-qDqycsMw_diPoSOKDmjhGbnL3HwZMCEPCHslBDOZCK2UI_KwTCJ2Ps26m0oe2g_hE9CSJoStov2KBNiyKXsoY8nV4GZVtpjHVowXcCuxONq2ulad4CLefAwjnhnXXOBbd1W1iyPgEvncTAT--XaiYfGaqybAtto0XnQXQ1Nd4B2Sl0FOFzvPnq7vXkd3SePz3cPo-vHxAgquiQjLBUaeDZIh7lmUOZGgyRxc52xeEtpKOORVqSaUk4gNSyTXHCTQ25S3keXK992mtdQmBjtdaVab2vt58ppq_4ijZ2osZuplBHOMxoNxMrAeBfiy-VGS4laFK6WhatFm4owtSxciag7_h38o1o3HAlXKwLE92cWvArGQmOgsD7WrQpn_4n4BqEslBc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Konradi, Christine ; Heckers, Stephan</creator><creatorcontrib>Konradi, Christine ; Heckers, Stephan</creatorcontrib><description>The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the number of their connections are determined by the activity of the glutamate system and its receptors. Malfunctions of the glutamate system affect neuroplasticity and can cause neuronal toxicity. In schizophrenia, many glutamate-regulated processes seem to be perturbed. Abnormal neuronal development, abnormal synaptic plasticity, and neurodegeneration have been proposed to be causal or contributing factors in schizophrenia. Interestingly, it seems that the glutamate system is dysregulated and that
N-methyl-
d-aspartate receptors operate at reduced activity. Here we discuss how the molecular aspects of glutamate malfunction can explain some of the neuropathology observed in schizophrenia, and how the available treatment intervenes through the glutamate system.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/S0163-7258(02)00328-5</identifier><identifier>PMID: 12559388</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Antipsychotic drugs ; Glutamate ; Glutamates - metabolism ; Glutamates - physiology ; Glutamates - therapeutic use ; Humans ; Neuropathology ; Neuroplasticity ; Neurotoxicity ; Neurotransmitter Agents - physiology ; Receptors, Glutamate - classification ; Receptors, Glutamate - physiology ; Receptors, Glutamate - therapeutic use ; Receptors, N-Methyl-D-Aspartate - drug effects ; Receptors, N-Methyl-D-Aspartate - physiology ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - etiology ; Schizophrenia - pathology ; Signal Transduction - drug effects</subject><ispartof>Pharmacology & therapeutics (Oxford), 2003-02, Vol.97 (2), p.153-179</ispartof><rights>2002 Elsevier Science Inc.</rights><rights>Copyright 2002 Elsevier Science Inc.</rights><rights>2002 Elsevier Science Inc. All rights reserved. 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-60245ae36749ba2efbcae80efb3a622ef88c123602d4a1130e4c268353cbebc43</citedby><cites>FETCH-LOGICAL-c515t-60245ae36749ba2efbcae80efb3a622ef88c123602d4a1130e4c268353cbebc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0163-7258(02)00328-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12559388$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Konradi, Christine</creatorcontrib><creatorcontrib>Heckers, Stephan</creatorcontrib><title>Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment</title><title>Pharmacology & therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the number of their connections are determined by the activity of the glutamate system and its receptors. Malfunctions of the glutamate system affect neuroplasticity and can cause neuronal toxicity. In schizophrenia, many glutamate-regulated processes seem to be perturbed. Abnormal neuronal development, abnormal synaptic plasticity, and neurodegeneration have been proposed to be causal or contributing factors in schizophrenia. Interestingly, it seems that the glutamate system is dysregulated and that
N-methyl-
d-aspartate receptors operate at reduced activity. Here we discuss how the molecular aspects of glutamate malfunction can explain some of the neuropathology observed in schizophrenia, and how the available treatment intervenes through the glutamate system.</description><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic drugs</subject><subject>Glutamate</subject><subject>Glutamates - metabolism</subject><subject>Glutamates - physiology</subject><subject>Glutamates - therapeutic use</subject><subject>Humans</subject><subject>Neuropathology</subject><subject>Neuroplasticity</subject><subject>Neurotoxicity</subject><subject>Neurotransmitter Agents - physiology</subject><subject>Receptors, Glutamate - classification</subject><subject>Receptors, Glutamate - physiology</subject><subject>Receptors, Glutamate - therapeutic use</subject><subject>Receptors, N-Methyl-D-Aspartate - drug effects</subject><subject>Receptors, N-Methyl-D-Aspartate - physiology</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - etiology</subject><subject>Schizophrenia - pathology</subject><subject>Signal Transduction - drug effects</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUEtLAzEQDqJorf4EJUc9rOax2aYeFCm-QPGggidDNjvbRnY3S7It1F9v-qDqycsMw_diPoSOKDmjhGbnL3HwZMCEPCHslBDOZCK2UI_KwTCJ2Ps26m0oe2g_hE9CSJoStov2KBNiyKXsoY8nV4GZVtpjHVowXcCuxONq2ulad4CLefAwjnhnXXOBbd1W1iyPgEvncTAT--XaiYfGaqybAtto0XnQXQ1Nd4B2Sl0FOFzvPnq7vXkd3SePz3cPo-vHxAgquiQjLBUaeDZIh7lmUOZGgyRxc52xeEtpKOORVqSaUk4gNSyTXHCTQ25S3keXK992mtdQmBjtdaVab2vt58ppq_4ijZ2osZuplBHOMxoNxMrAeBfiy-VGS4laFK6WhatFm4owtSxciag7_h38o1o3HAlXKwLE92cWvArGQmOgsD7WrQpn_4n4BqEslBc</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>Konradi, Christine</creator><creator>Heckers, Stephan</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20030201</creationdate><title>Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment</title><author>Konradi, Christine ; Heckers, Stephan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-60245ae36749ba2efbcae80efb3a622ef88c123602d4a1130e4c268353cbebc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic drugs</topic><topic>Glutamate</topic><topic>Glutamates - metabolism</topic><topic>Glutamates - physiology</topic><topic>Glutamates - therapeutic use</topic><topic>Humans</topic><topic>Neuropathology</topic><topic>Neuroplasticity</topic><topic>Neurotoxicity</topic><topic>Neurotransmitter Agents - physiology</topic><topic>Receptors, Glutamate - classification</topic><topic>Receptors, Glutamate - physiology</topic><topic>Receptors, Glutamate - therapeutic use</topic><topic>Receptors, N-Methyl-D-Aspartate - drug effects</topic><topic>Receptors, N-Methyl-D-Aspartate - physiology</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - etiology</topic><topic>Schizophrenia - pathology</topic><topic>Signal Transduction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Konradi, Christine</creatorcontrib><creatorcontrib>Heckers, Stephan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacology & therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Konradi, Christine</au><au>Heckers, Stephan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment</atitle><jtitle>Pharmacology & therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>97</volume><issue>2</issue><spage>153</spage><epage>179</epage><pages>153-179</pages><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the number of their connections are determined by the activity of the glutamate system and its receptors. Malfunctions of the glutamate system affect neuroplasticity and can cause neuronal toxicity. In schizophrenia, many glutamate-regulated processes seem to be perturbed. Abnormal neuronal development, abnormal synaptic plasticity, and neurodegeneration have been proposed to be causal or contributing factors in schizophrenia. Interestingly, it seems that the glutamate system is dysregulated and that
N-methyl-
d-aspartate receptors operate at reduced activity. Here we discuss how the molecular aspects of glutamate malfunction can explain some of the neuropathology observed in schizophrenia, and how the available treatment intervenes through the glutamate system.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>12559388</pmid><doi>10.1016/S0163-7258(02)00328-5</doi><tpages>27</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-7258 |
| ispartof | Pharmacology & therapeutics (Oxford), 2003-02, Vol.97 (2), p.153-179 |
| issn | 0163-7258 1879-016X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4203361 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Antipsychotic drugs Glutamate Glutamates - metabolism Glutamates - physiology Glutamates - therapeutic use Humans Neuropathology Neuroplasticity Neurotoxicity Neurotransmitter Agents - physiology Receptors, Glutamate - classification Receptors, Glutamate - physiology Receptors, Glutamate - therapeutic use Receptors, N-Methyl-D-Aspartate - drug effects Receptors, N-Methyl-D-Aspartate - physiology Schizophrenia Schizophrenia - drug therapy Schizophrenia - etiology Schizophrenia - pathology Signal Transduction - drug effects |
| title | Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T04%3A53%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20aspects%20of%20glutamate%20dysregulation:%20implications%20for%20schizophrenia%20and%20its%20treatment&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Konradi,%20Christine&rft.date=2003-02-01&rft.volume=97&rft.issue=2&rft.spage=153&rft.epage=179&rft.pages=153-179&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/S0163-7258(02)00328-5&rft_dat=%3Cpubmed_cross%3E12559388%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12559388&rft_els_id=S0163725802003285&rfr_iscdi=true |